98%
921
2 minutes
20
Purpose: Chronic rhinosinusitis (CRS) is a frequent, quality-of-life (QOL) impairing disease in pediatrics. The SN-5 is a reliable, sensitive and reproductible QOL questionnaire, validated in English for evaluation of CRS disease-specific QOL in children. This study aims to adapt and validate the French version of this test.
Methods: The SN-5 score was adapted into French language through a forward-backwards translation process, and validated through a monocentric prospective controlled study. Inclusion criteria were 2-12 years of age, CRS symptoms for at least 12 weeks, or absence of sino-nasal symptom for controls. Reproducibility was assessed through Spearman's correlation between initial answers and a re-test conducted 15 days later. Internal consistency was measured through Cronbach's alpha, construct validity through Spearman's correlation between items, discriminative ability through Mann-Whitney tests.
Results: 40 patients and 37 controls filled the score between November 2019 and March 2020. Retest was returned by 35 patients and 35 controls. Mean cases age was 8.5 ± 2.6 years old. 26 patients had primary CRS, 10 had cystic fibrosis, 4 had ciliary dyskinesia. All had diffuse disease. Mean SN-5 overall score was 3.63/7 ± 6.4 for CRS patients and 1.89/7 ± 0.9 for controls (p < 0.001). Test-retest coefficient was 0.84 (0.70-0.92; p < 0.001), Cronbach's alpha was 0.83 for CRS patient. Item per item construct validity was good to excellent.
Conclusions: The French version of the SN-5 showed good statistical properties, with good test-retest reliability, internal consistency, structural validity and discriminative ability between CRS and control patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijporl.2021.110706 | DOI Listing |
Cureus
July 2025
College of Medicine, Jazan University, Jazan, SAU.
Chronic rhinosinusitis (CRS), with or without nasal polyps (CRSwNP/CRSsNP), is a prevalent inflammatory condition of the sinonasal mucosa, for which intranasal corticosteroids (INCS) are widely used as first-line therapy. This systematic review evaluated the efficacy and safety of INCS, used alone or with adjunctive treatments, in improving clinical outcomes in CRS patients. A comprehensive literature search was conducted across PubMed, Cochrane Library, Scopus, Web of Science, and the Virtual Health Library (VHL) through May 2025, including randomized controlled trials (RCTs) assessing INCS efficacy in adults and children with CRS.
View Article and Find Full Text PDFInt J Pediatr Otorhinolaryngol
July 2025
Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, US. Electronic address:
Objective: To assess test-retest reliability, validity, responsiveness, and clinical interpretability of the SNOT-22 in identifying pediatric patients with CRS from healthy, non-CRS patients by comparing SNOT-22 and SN-5 across multiple visits.
Study Design: Prospective cohort; all pediatric patients between the ages of 6-17, or under the age of 6 but fully verbal, who presented for care between January 2022 through March 2024.
Setting: Tertiary care academic institution's pediatric otolaryngology clinic.
Int Forum Allergy Rhinol
July 2025
Service d'Otorhinolaryngologie, Hôpital Necker Enfants malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France.
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation. The purpose of this study is to evaluate the impact of ETI on CRS symptoms in children and adolescents with CF.
Methods: The MODUL-CF observational study is a multicenter prospective cohort study enrolling CF children with at least 1 F508del mutation in France.
Int Forum Allergy Rhinol
July 2025
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Background: Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector-potentiator drug. In people with cystic fibrosis age > 12 years, ETI improves sinonasal symptoms, endoscopy findings, polyp size, and radiologic findings.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Boulevard Pinel, Lyon, France.
Background: New CFTR Modulator triple therapy Elexacaftor-Ivacaftor-Tezacaftor (ETI) prove efficacy in pulmonary outcomes. However, its impact on nasal sinus symptoms in children has not been specifically studied. The aim of this study is to evaluate the impact of this therapy on nasal sinus symptomatology in children aged 6-12 years.
View Article and Find Full Text PDF